Leveraging Real-World Data for Regulatory Submissions in US, EU and UK


Leveraging Real-World Data for Regulatory Submissions in US, EU and UK

Leveraging Real-World Data for Regulatory Submissions in US, EU and UK

Context

In the rapidly evolving landscape of regulatory affairs, the integration of real-world data (RWD) into regulatory submissions has become a critical focal point for pharmaceuticals and biotechnology companies. RWD provides insights derived from real-world evidence (RWE) that reflects the use of medical products in routine practice, rather than controlled clinical trials. This article elucidates the application of RWD and emerging regulatory policy trends, particularly in the context of service pharmacovigilance.

Legal/Regulatory Basis

Understanding the legal frameworks governing the use of RWD and RWE in regulatory submissions is imperative for regulatory affairs professionals. In the United States, the Food and Drug Administration (FDA) has established guidelines that encourage the utilization of RWD to support regulatory decision-making, specifically under the Real-World Evidence Program. The 21st Century Cures Act further emphasizes the importance of RWE for new indications, changes in labeling, and post-market surveillance.

In the European Union (EU), the European Medicines Agency (EMA) has issued detailed guidance on the use of RWE in regulatory submissions, particularly in the context of marketing authorization applications and post-marketing studies. Notably, the Guideline

on the use of RWD for the assessment of medicinal products lays the groundwork for the submission of RWD as part of the benefit-risk assessment process.

Similarly, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has adopted a position in line with its EU counterparts, recognizing the significance of RWD in the regulatory evaluation phase. The MHRA’s focus on leveraging real-world data signifies a commitment to a patient-centered approach to drug assessment.

Documentation

Proper documentation is essential for FDA, EMA, and MHRA submissions involving RWD. Regulatory affairs professionals must ensure that the following elements are included:

  • Study Design: Detailed descriptions of how RWD is collected must be provided, including methodologies, data sources, and population characteristics.
  • Data Quality and Integrity: It is critical to present robust evidence demonstrating that the data is reliable and relevant to the question being addressed.
  • Statistical Analysis: Clear and transparent analysis plans, including both exploratory and confirmatory analyses, must be detailed to validate findings.
  • Risk Assessment: It should incorporate the evaluation of potential biases and limitations inherent in RWD studies.
  • Regulatory Compliance: Ensure that all data governance regulations are addressed, particularly regarding patient privacy and ethical considerations.
See also  Global Guidance on Real-World Evidence: FDA, EMA and MHRA Compared

Review/Approval Flow

The approval process for submissions utilizing RWD can vary significantly between regions. Understanding these nuances is critical for effective regulatory planning. The approval flow typically involves the following steps:

  1. Pre-Submission Meetings: Engage relevant regulatory authorities early to discuss intentions regarding RWD utilization. This step ensures alignment with agency expectations and addresses any preliminary concerns.
  2. Submission of RWD-dominated Applications: Follow through with the formal submission of applications that incorporate RWD. Include comprehensive documentation, as outlined in the previous section.
  3. Agency Review: Regulatory bodies will conduct a thorough evaluation of the submitted data, assessing the integrity and applicability of the findings to ensure that RWD can support the therapeutic claims presented.
  4. Post-Approval Commitments: Be prepared for potential post-marketing commitments to conduct further studies involving RWD, especially if the application involves a novel indication or significant change in the risk profile of a product.

Common Deficiencies

Common deficiencies encountered when submitting RWD-related applications often include:

  • Poor Data Quality: Insufficient data quality can lead to questions regarding the validity of findings. Ensuring robust data management practices is crucial to mitigate this risk.
  • Lack of Justification for RWD Use: If the rationale for choosing to use RWD is not sufficiently articulated, submissions may be deemed inadequate.
  • Inadequate Statistical Rigor: Failure to apply appropriate statistical methods can result in regulatory pushback. Using established methodologies for analyzing RWD is essential.
  • Insufficient Documentation: Failing to provide comprehensive documentation can hamper regulatory decisions. Ensure all required components are clearly presented in the submission package.

RA-Specific Decision Points

Variation vs. New Application

Deciding whether to file a variation or a new application based on RWD can involve complex decision-making. Key considerations include:

  • Extent of Change: Assess whether the proposed changes impact the fundamental pharmacological properties of the product.
  • Regulatory Guidance: Reference specific regulatory guidelines that provide context for the classification of the change.
  • Potential Risk Assessment: Evaluate whether the new data constitutes a significant increase in risk or an important new therapeutic benefit.
See also  Using RWE to Support Label Expansion, Safety Updates and Post-Authorisation Changes

Justifying Bridging Data

When using bridging data to support claims made in submissions, consider the following:

  • Relevance of Data: Clearly demonstrate how the bridging studies are relevant to the current submission and how they correlate with the proposed indications.
  • Consistency with Prior Findings: Show how prior research findings support the conclusions drawn from the new data.
  • Expert Consensus: Where possible, include opinions from therapeutic area experts to strengthen the justification for utilizing bridging data in submissions.

Inter-Departmental Interactions

Efficient communication and collaboration among regulatory affairs (RA), Chemistry, Manufacturing and Controls (CMC), Clinical, Pharmacovigilance (PV), Quality Assurance (QA), and Commercial teams are pivotal in successfully navigating the complexities of RWD submissions. Specific interactions include:

  • CMC: Ensure that CMC teams provide data supporting the manufacturing process to complement RWD findings, including any deviations that could affect risk evaluations.
  • Clinical: Collaborate closely with clinical teams to ensure that RWD aligns with clinical evidence presented, thus maintaining consistency in therapeutic objectives.
  • Pharmacovigilance: Coordinate with PV teams to monitor safety signals arising from RWD and confirm alignment with post-marketing commitments.
  • Quality Assurance: Verify that data collection processes adhere to QA standards throughout RWD studies to uphold integrity in findings.
  • Commercial: Engage with commercial partners to align RWD strategies with market access frameworks and commercial objectives.

Practical Tips

To optimize the use of RWD in regulatory submissions, consider the following practical strategies:

  • Early Stakeholder Engagement: Initiate discussions with regulatory authorities early in the development process to clarify expectations regarding RWD.
  • Thorough Planning: Develop a comprehensive RWD strategy that outlines objectives, data sources, and analytical methods before commencement.
  • Regular Training: Ensure that the regulatory affairs team stays updated on emerging regulatory trends and best practices through training and professional development
See also  Health Technology Assessment and RWE: Implications for Regulatory Affairs

The Future of Regulatory Affairs

The integration of artificial intelligence and digital health technologies is poised to further revolutionize regulatory practices. As the convergence of global regulations continues, adaptability, and proactive strategies will be paramount for success in leveraging service pharmacovigilance and real-world evidence for regulatory submissions across regions.

In conclusion, the utilization of real-world data in regulatory submissions presents both opportunities and challenges for regulatory affairs professionals in the US, EU, and UK. By adhering to established guidelines, proactively engaging regulatory bodies, and ensuring rigorous documentation practices, companies can navigate the evolving landscape of regulatory affairs effectively.

Related Guidelines: